Status:
COMPLETED
Perioperative Patient Skin Antiseptic Preparation Evaluation
Lead Sponsor:
Zurex Pharma, Inc.
Conditions:
Surgical Site Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate a new topical skin antiseptic perioperative preparation and the standard of care to determine efficacy on the rates of surgical site infections of surgical patients. Safety wi...
Eligibility Criteria
Inclusion
- Be male or female and at least 18 years of age.
- Be able to verbalize an understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English.
- Be planning to undergo clean (class I wound) or clean-contaminated (class II wounds) surgery.
- Expect to be available for up to 30-days after the surgery.
Exclusion
- Active infection or fever including evidence of infection at or adjacent to the operative site.
- Immunosuppressed.
- Kidney/liver failure.
- Immunosuppressive therapy (chemotherapy, steroids) within the previous 1 week.
- Any history of allergy to chlorhexidine or isopropyl alcohol or any other component in ZuraGard including citric acid, sodium citrate, methylparaben, or propylparaben, and FD\&C Yellow #6.
Key Trial Info
Start Date :
June 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 29 2022
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT04756804
Start Date
June 21 2021
End Date
September 29 2022
Last Update
March 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MCW/FH
Milwaukee, Wisconsin, United States, 53226